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Background: The RV144 trial showed promise towards the 
development of an effective HIV vaccine, Antibodies to HIV 
Env VIV2 loop, Env-specific IgA and HLA class II DQBL*06 
allele with high Env IgA were all significantly associated with 
risk of infection. 
Methods: We used an integrated systems biology approach to 
identify novel correlates of immunogenicity and/or protection. 
Env-specific stimulated peripheral blood mononuclear cells 
from RV144 participants were used to test the hypothesis that 
innate pro-inflammatory responses would demarcate RVl44 
case-control groups. 
Results: A case/control gene expression analysis using 133 
controls and 27 cases yielded few significantly differentially 
expressed genes between cases and controls, To adjust for the 
heterogeneity and the case/control class imbalance, we em-
ployed a stratification strategy using a tree-based classification 
method with IgA, V!V2 and DQB1*06 as predictor variables 
and the infection status as the outcome. The obtained tree model 
showed a balanced accuracy of 61 % and identified two different 
risk groups. Cases in the first group had low IgA titers and did 
not express the DQB 1 *06 allele. Transcriptional profiling 
showed downregulation of the type ll interferon induced genes 
(Fisher enrichment test p value "" 0.04) in these cases compared 
to controls. Cases in the second Group had high IgA and Low 
VIV2 titers, Transcriptional profiling showed, interestingly, up-
regulution of several type I interferon genes including antiviral 
genes (Fisher enrichment test p value = 10-6) in these cases 
compared to controls. 
Conclusions: Herein we have identified a gene expression sig-
nature, segregating case and control donors and which, coun-
terintuitively, shows contrasting roles for innate immune 
response genes in conferring vaccine induced protection. These 
results have important implications for the development of more 
effective HIV vaccine strategies. 
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Background: Understanding molecular mechanisms of natural 
disease control in the absence of treatment in a minor group of 
HIV-infected subjects, identified as slow progressors (SP), rep-
resents a logical approach towards a potential functional cure. 
Methods: In the current study we aimed to identify molecular 
signatures associated with viral control in our Canadian cohort 
of HIV-infected SP (Study # CTN 247; subjects maintaining 
CD4 counts over 500/microliter for over 7 years, in the absence 
of treatment). To this end, we have identified 5 subjects that have 
experienced a sudden loss of viral control (average increase of 
viral load: 5 to 79 fold) and a decline in the absolute CD4 counts 
(average loss: 211 cells/microliter). We used the Illumina 
technology to study genome-wide transcriptional profiles in 
peripheral blood mononucleated cells {PBMCs) isolated from 
these subjects before (Visit l) and after (Visit 2) the loss of 
virological control. 
Rl'sults: Our analysis identified 1,381 probe sets corresponding 
to 1,268 genes that were differentially expressed between VI 
and V2 (nominal p-value<5%). Among these genes, 864 were 
downregulated and 517 were upregulated at V2 versus VI. Of 
note, among the down-regulated genes, several members of 
both innate and adaptive anti-viral responses were identified 
such as APOBEC3G, IL-32, the T cell receptor CD96 (known 
to associated with the superior quality of CD& T cells in HIV-
it1fected Elite controllers), Lek, LAT, JAKl, ITK and the IL-7 
receptor (IL-7R). Our validation assays are currently in prog-
ress to validate the expression of these genes at the protein 
level. 
Conclusions: Our current study takes advantage of the power of 
the whole genome transcriptional analysis on privileged samples 
from HIV-infected SP subjects before and after the Joss of vi-
rological control to identify new targets for therapeutic inter-
ventions and also to identify early biomarkers to predict disease 
progression. 
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Background: Recent reports in humanized mice and monkeys 
have found that broadly neutralizing antibodies (bNAbs) can 
suppress the replication of laboratory strains of HIV and 
SHIV while bNAb concentration remains high. Vectored Im-
munoProphylaxis (VIP) results in long-lived bNAb expression 
following a single intramuscular {IM) injection of a specialized 
vim\ vector, and this approach has been demonstrated as a means 
of durably suppressing viral load. However, previous reports of 
VIP-delivered bNAbs for HIV therapy required prior antiretroviral 
drug therapy to reduce viral load to prevent escape. 
Methods: Humanized BLT mice were infected IV with the 
REJO.c transmitted molecular founder strain ofHlV. A low dose 
of combination antiretroviral therapy (ART) was administered to 
these animals for 5 weeks, followed by a single h\f injection of 
VIP expressing VRC07 or luciferase. Mouse plasma was ana-
lyzed by ELISA to detennine antibody concentration and by 
qPCR to determine viral load. Cellular fractions were analyzed 
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by flow cytometry to quantify human CD4 cells over time. After 
sacrifice, plasma was subjected to a clinically validated ultra-
sensitive PCR-based viral load assay. 
Results: We detected viral loads of 105 copies/mL in infected 
mice prior to low-dose ART treatment, which resulted in a 
transient reduction and rebound to pre-therapy loads. Following 
VIP administration, we observed a rapid increase in the blood 
concentration of VRC07. Mice expressing VRC07 exhibited a 
sharp decline in viral load to undetectable levels and an increase 
in CD4 cells over four weeks and this effect was sustained for the 
remaining S weeks of the study. In contrast, mice expressing 
luciferase exhibited increasing viral loads with concomitant 
decreases in CD4 cells throughout the study. 
Conclusions: Our results demonstrate that VIP expressing VRC07 
is sufficient to suppress actively replicating transmitted founder 
virus at high viral load and support efforts to move Vectored Im-
munoTherapy into clinical trials with infected patients. 
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Backgt'ound: Eliciting HIV-specific immune responses through 
vaccination remains an important goal in preventing HIV. Here 
we present safety, tolerability, and immunogenicity data from a 
phase fa trial of a novel HIV-I multi-antigen (MAG) DNA 
vaccine delivered by electroporation (EP) with DNA IL-12 ad-
juvant and boosted with an rVSV HIV-1 Gag vaccine. 
Methods: HVTN OS7 enrolled 100 healthy adults in a multi-
center, randomized, double-blinded, placebo-controlled study. 
Participants received 3,000mcg HIV-MAG (gag/pol, env, nef/ 
tat/vij) DNA vaccine co-administered with IL-12 DNA at 0, 250, 
1000, or 1500mcg (N=22/group) or placebo (N=3/group) in-
tramuscularly by EP at 0, 1 and 3 months boosted by rVSV Gag 
vaccine or placebo at 6 months. Participants were assessed for 
reactogenicity, tolerability, and adverse events. CD4 + and 
CDS+ T-cell responses to HIV potential T-cell epitope (PTE) 
peptides were measured by intracellular cytokine staining (ICS) 
2 weeks after 3rd and 4th vaccinations. 
Results: EP was generally well tolerated. Local and systemic 
reactogenicity symptoms were generally mild to moderate. After 
the 4th vaccination some subjects experienced moderate to se-
vere systemic symptoms and several experienced transient 
lyrnphopenia. After DNA prime, CD4+ T-cell responses to any 
PTE were detected in 77% of subjects and CDS+ T·cell re· 
sponses in 40%. Gag-specific CD4+ T-cell response rates after 
DNA prime increased significantly following rVSV Gag boost, 
from 15% to S6%. Gag-specific CDS+ T-cell responses also 
increased significantly from 6% after DNA prime to 26% after 
rVSV Gag boost. IL-12 DNA 1500 rncg increased the magnitude 
of CDS+ T·cell responses compared to no !L-12 DNA 
(p=0.02). 
Conclusions: HIV-I DNA vaccination given by EP with IL-12 
and boosted with HIV-rVSV is safe and immunogcnic. DNA!EP 
prime dramatically improves T-cell responses after a single 
rVSV boost compared with rVSV homologous prime-boost 
(HVTN 090). Il-12 DNA does not increase response rates but 
increases the magnitude of CDS+ T-cell responses. 
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Backgrnund: GV-TH-01, a Phase 1 ope11-Jabel trial ofGOVX-
Bll, a DNA/MVA prime-boost regimen, in HIV infected pa-
tients on ART was undertaken to evaluate safety and vaccine-
elicited T cell responses, and to explore viral rebound during 
analytical treatment interruption {TI). 
Methods: Patients who began ART within IS months of sero~ 
conversion and had sustained plasma HIV-I RNA<50 c/mL for 
at least 6 months were enrolled. Patients received a total of 4 
inoculations at intervals of S weeks. 2 of pGA2/JS7 DNA (3mg) 
followed by 2 of MV A!HIV62B (I 08 TCID50). At 8 weeks after 
the last immunization, plus an efavirenz wash-out if needed, 
participants entered a TI phase of 12 weeks, after which ART 
was reinstituted. T cell responses were scored for IFNg or IL2 by 
flow cytometry following stimulation with Gag, Env and Pol 
peptides. Responses were considered positive if ~2-fold higher 
than pre-vaccination. 
Results: S of 9 men completed all vaccinations. For the S, me-
dian age was 37.5yrs, baseline CD4 count was 691/,uL (50!-
1612/til) and all had HIV- I RNA <50 c/rnL. Median viral load 
prior to ART was 5.1 log!O c/mL (2.6·7.2 log!O c/mL). No 
serious adverse events occurred. After the 1'1 or 2"d MV Al 
HIV62B immunization, Gag-specific CDS T cells were boosted 
over pre· vaccination levels in 7 out of S (P < 0.05) whereas Gag-
specific CD4 T cells were boosted in 5 of S patients (P=0.2). 6 
of S patients elicited previously undetectable CDS responses 
whereas 5 of S elicited previously undetectable CD4 responses 
to Gag epitopes. Gp120 or gp41-spccific antibody responses 
were boosted in 3 of S patient and 2 of 8 patients respectively. 
Excluding one acute seroconverter, the median reduction in 
HIV-1 RNA at weeks 2, 6, and 12 compared to pre-ART levels 
was -2.2, -1.3 and -0.8 loglO c/mL. 
Conclusions: This trial demonstrates the potential for GOVX-
B 11 to boost both T cell and antibody responses in a therapeutic 
setting. A placebo-controlled trial will be required to further 
assess the therapeutic benefit of the \'accine. 
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